Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
In light of the intriguing potential of anti-angiogenic approach in suppressing choroidal neovascularization, we attempted to elaborate synthetic gene delivery systems encapsulating anti-angiogenic plasmid DNA as alternatives of clinical antibody-based therapeutics. Herein, block copolymer of cyclic...
Guardado en:
Autores principales: | Jing Wang, Xiang Shi, Qiyu Bo, Hong Wang, Fang Wei, Jun Liu, Hao Wang, Liuwei Zhang, Yan Qi, Zhen Li, Qixian Chen, Xiaodong Sun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca1aa189273b4b769d0432308785638f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021) -
Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016) -
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019) -
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)